The demand for dengue vaccines in Japan is projected to grow from USD 4.9 million in 2025 to USD 9.0 million by 2035, at a CAGR of 6.2%. Dengvaxia will dominate with a 48.0% market share, while adult will lead the age group segment with a 35.0% share.